GlaxoSmithKline plc (LON:GSK) was upgraded by research analysts at Citigroup Inc. to a “buy” rating in a research note issued on Wednesday, MarketBeat.Com reports. The firm presently has a GBX 1,550 ($22.07) price objective on the stock. Citigroup Inc.’s price objective suggests a potential upside of 11.35% from the stock’s current price.
GSK has been the topic of several other reports. Sanford C. Bernstein restated a “market perform” rating and set a GBX 1,399 ($19.92) price objective on shares of GlaxoSmithKline plc in a report on Monday, January 4th. Natixis reiterated a “neutral” rating and issued a GBX 1,470 ($20.93) target price on shares of GlaxoSmithKline plc in a research report on Wednesday, January 13th. AlphaValue reiterated an “add” rating and issued a GBX 1,536 ($21.87) target price on shares of GlaxoSmithKline plc in a research report on Thursday, March 10th. Deutsche Bank lifted their target price on GlaxoSmithKline plc from GBX 1,500 ($21.36) to GBX 1,540 ($21.92) and gave the stock a “hold” rating in a research report on Monday, January 18th. Finally, BNP Paribas reiterated a “neutral” rating and issued a GBX 1,400 ($19.93) target price on shares of GlaxoSmithKline plc in a research report on Friday, January 8th. Two research analysts have rated the stock with a sell rating, eighteen have issued a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of GBX 1,503.92 ($21.41).
Source: American Banking and Market News